Skip to search formSkip to main contentSkip to account menu

NBI-98854

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

valbenazine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
BACKGROUND Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment… 
2017
2017
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
BACKGROUND The short-term safety profile of once-daily valbenazine (NBI-98854) has been evaluated in several double-blind… 
2017
2017
Pharmacologic Characteristics of Valbenazine (NBI-98854) and its Metabolites (P2.025)
Objective: To characterize the pharmacology of valbenazine and its metabolites in vitro . Background: Valbenazine (NBI-98854), a… 
2017
2017
Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of Long-Term Exposure Data from Three Studies (P2.017)
Objective: To assess the long-term safety and tolerability of valbenazine (NBI-98854) for the treatment of tardive dyskinesia (TD… 
2017
2017
Efficacy of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of a Long-Term Study (KINECT 3 Extension) (S56.005)
Objective: To assess the long-term efficacy of valbenazine (NBI-98854) in treating tardive dyskinesia (TD). Background… 
2016
2016
Open-Label Extension of KINECT: A Phase 2 Study of Valbenazine (NBI-98854) for Tardive Dyskinesia (S27.001)
Objective: To assess safety, tolerability and persistence of effect of valbenazine in subjects with schizophrenia or… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)